Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Completes MQ-9B 'Flight Into Known Icing' Flight Tests20.4.2026 15:00:00 CEST | Press release
Global RPA Leader Is Certifying MQ-9B for FIKI SAN DIEGO, CA / ACCESS Newswire / April 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has conducted a series of flight tests aimed at certifying the MQ-9B Remotely Piloted Aircraft (RPA) for Flight Into Known Icing (FIKI). The flight tests began last year, and all planned testing was successfully completed in early April from GA-ASI's Flight Test & Training Center (FTTC) near Grand Forks, North Dakota, using a company-owned MQ-9B. The FIKI flights build on earlier successful flight tests to evaluate flight characteristics with simulated ice shapes adhered to the aircraft as well as the aircraft's successful Cold Weather Validation and flights in the Arctic. FIKI certification will expand MQ-9B's abilities to provide all-weather surveillance capabilities for the many nations that have purchased the system for their military and civil support missions. The tests were flown using GA-ASI Internal Research and Development fundi
GA-ASI Completes MQ-9B 'Flight Into Known Icing' Flight Tests20.4.2026 15:00:00 CEST | Press release
Global RPA Leader Is Certifying MQ-9B for FIKI SAN DIEGO, CA / ACCESS Newswire / April 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has conducted a series of flight tests aimed at certifying the MQ-9B Remotely Piloted Aircraft (RPA) for Flight Into Known Icing (FIKI). The flight tests began last year, and all planned testing was successfully completed in early April from GA-ASI's Flight Test & Training Center (FTTC) near Grand Forks, North Dakota, using a company-owned MQ-9B. The FIKI flights build on earlier successful flight tests to evaluate flight characteristics with simulated ice shapes adhered to the aircraft as well as the aircraft's successful Cold Weather Validation and flights in the Arctic. FIKI certification will expand MQ-9B's abilities to provide all-weather surveillance capabilities for the many nations that have purchased the system for their military and civil support missions. The tests were flown using GA-ASI Internal Research and Development fundi
Loar Holdings Inc. Announces Date and Time for First Quarter 2026 Earnings and Conference Call17.4.2026 15:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / April 17, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2026 earnings before the market opens on Thursday, May 7, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670/+1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact: Ian McKillop Loar Holdings Inc. Investor Relatio
Loar Holdings Inc. Announces Date and Time for First Quarter 2026 Earnings and Conference Call17.4.2026 15:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / April 17, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2026 earnings before the market opens on Thursday, May 7, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670/+1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact: Ian McKillop Loar Holdings Inc. Investor Relatio
Karbon-X Launches SkyXero, a New App for Flight Emissions Tracking as Travelers Seek Trusted Climate Solutions17.4.2026 15:00:00 CEST | Press release
New mobile app enables real-time flight emissions tracking and access to verified climate projects worldwide, launching during Earth Month. CALGARY, AB / ACCESS Newswire / April 17, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today announced the launch of SkyXero, a new mobile application that enables travelers to measure and balance the emissions of their flights in a few taps. Launching during Earth Month, a period of heightened global focus on environmental impact, SkyXero is now available globally and is designed to meet the growing demand from travelers seeking practical, trusted ways to incorporate climate considerations into their travel decisions. SkyXero allows users to enter flight details, instantly calculate associated emissions, and contribute to a curated portfolio of high-integrity, third-party verified climate projects, including those certi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom